Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with …
…, V Thiyagarajan, T Lewis, L Gruberg… - JAMA internal …, 2021 - jamanetwork.com
Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. …
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. …
The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal …
BACKGROUND Acute deterioration in renal function is a recognized complication after coronary
angiography and intervention. OBJECTIVES The goal of this study was to determine the …
angiography and intervention. OBJECTIVES The goal of this study was to determine the …
The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox?
L Gruberg, NJ Weissman, R Waksman, S Fuchs… - Journal of the American …, 2002 - jacc.org
Objectives : The purpose of this study was to assess the impact of body mass index (BMI) on
the short- and long-term outcomes after percutaneous coronary intervention (PCI). …
the short- and long-term outcomes after percutaneous coronary intervention (PCI). …
[HTML][HTML] Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16
…, L Gruberg, JE Balow Jr, L Prosen… - … England Journal of …, 1992 - Mass Medical Soc
Background. Familial Mediterranean fever is an autosomal-recessive disease characterized
by acute attacks of fever with sterile peritonitis, pleurisy, or synovitis. The biochemical basis …
by acute attacks of fever with sterile peritonitis, pleurisy, or synovitis. The biochemical basis …
Acute renal failure requiring dialysis after percutaneous coronary interventions
Acute renal failure requiring dialysis is a rare but serious complication after percutaneous
coronary interventions (PCI), associated with high in‐hospital mortality and poor long‐term …
coronary interventions (PCI), associated with high in‐hospital mortality and poor long‐term …
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
…, JR Day, RS Iwaoka, TD Stuckey, HS Gogia, L Gruberg… - The Lancet, 2013 - thelancet.com
Background Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that
was tested for percutaneous coronary intervention (PCI) in three large, double-blind, …
was tested for percutaneous coronary intervention (PCI) in three large, double-blind, …
Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications
S Fuchs, E Stabile, TD Kinnaird, GS Mintz, L Gruberg… - Circulation, 2002 - Am Heart Assoc
Background— Stroke associated with percutaneous coronary intervention (PCI) is an
infrequent although devastating complication. We investigated the incidence, predictors, and …
infrequent although devastating complication. We investigated the incidence, predictors, and …
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial
…, K Prather, JF Heitner, R Kilaru, L Gruberg… - Jama, 2011 - jamanetwork.com
Context Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause of
morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and …
morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and …
Incidence, management, and outcome of coronary artery perforation during percutaneous coronary intervention
L Gruberg, E Pinnow, R Flood, Y Bonnet… - American Journal of …, 2000 - ajconline.org
Coronary artery perforation is a rare but dreaded complication of percutaneous coronary
intervention (PCI). It has been reported to occur in 0.2% to 0.6% of all patients who undergo …
intervention (PCI). It has been reported to occur in 0.2% to 0.6% of all patients who undergo …
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial
…, R Gollapudi, M Goodwin, N Goswami, L Gruberg… - The Lancet, 2022 - thelancet.com
Background The SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled
Hypertension) trial showed the safety but not efficacy of the Symplicity system (Medtronic, Santa …
Hypertension) trial showed the safety but not efficacy of the Symplicity system (Medtronic, Santa …